Navigation Links
Mental Disorders Drugs Market - New Industry Research Report Is Now Available for Pre-Order at Transparency Market Research
Date:8/23/2013

Albany, New York (PRWEB) August 23, 2013

A mental disorder is a psychological anomaly that is reflected in the behavior of the patient through distress, disability or any conduct that is not a part of a person’s normal mental development. The causes of mental disorders are varied in nature and many are also unclear. Psychiatric medication and psychotherapy are the two modes of treatment for mental disorder. In psychiatric medication drug classes such as antidepressants, anxiolytics, and antipsychotics are most commonly used.

Browse the report with Request TOC at http://www.transparencymarketresearch.com/mental-disorders-drugs.html.

Improvement in patient security policy, growth in domestic and foreign investment in the field of mental medication, and increase in the prevalence and the related awareness about mental health are the major drivers for the global mental disorders drugs market. However, skepticism about social pressure regarding mental diseases and their treatment, especially in less advanced countries, and the lack of government initiatives in such locations may hold back the growth of this market.

The overall mental disorders drugs market can be classified on the basis of the mental drugs such as antidepressants, antipsychotics, anxiolytics, drugs for schizophrenia, drugs for childhood and adolescent mental illness, and drugs for the treatment of substance and alcohol addiction, bipolar disease drugs, and others.

North America is the largest market for mental disorders drugs. Factors such as increasing government initiatives, better reimbursement policies, and general awareness about mental health and treatment are responsible for the growth of this market in this region. An increase in the awareness about the efficacy of mental disorders’ drugs and growth in the related clinical evidence will assist in the rapid growth of this market in Asia-Pacific. The major players in the mental disorders drugs market include pharmaceutical manufacturers such as Eli Lilly, AstraZeneca, Pfizer, Johnson and Johnson, GlaxoSmithKline, and Bristol-Myers Squibb.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include:
North America
Asia Pacific
Europe
Rest of the World
This report provides comprehensive analysis of
Market growth drivers
Factors limiting market growth
Current market trends
Market structure
Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report
This report provides pin-point analysis for changing competitive dynamics
It provides a forward looking perspective on different factors driving or restraining market growth
It provides a technological growth map over time to understand the industry growth rate
It provides a seven-year forecast assessed on the basis of how the market is predicted to grow
It helps in understanding the key product segments and their future
It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
It provides distinctive graphics and exemplified SWOT analysis of major market segments

Browse all Market Research reports: http://www.transparencymarketresearch.com

Read the full story at http://www.prweb.com/releases/2013/8/prweb11056047.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Experimental Chemo Combo for Colon Cancer Disappoints
2. Mental Illness Tied to Higher Rates of Physical Problems: Report
3. Researchers ID Genes That May Determine Mental Illness
4. First contact: Early intervention key in diagnosis and treatment of serious mental illness
5. Media Multitasking Might Have Mental Upside
6. Experimental Pill for Multiple Sclerosis Shows Promise
7. Experimental Gel May Help Those With Advanced Parkinsons
8. Talking to Yourself Could Have Mental Benefits
9. Experimental Drug Eases Autistic Behaviors in Mice
10. Understanding and promoting mental health - Insights from psychological science
11. Developmental Woes Common in Siblings of Children With Autism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... to revolutionize the emergency ambulance transport experience for the millions of people who ... Uber has disrupted the taxi industry through the use of technology. Now, SmartEMS ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
(Date:6/24/2016)... 24, 2016 According to a ... (Standard Pen Needles, Safety Pen Needles), Needle Length (4mm, ... Hormone), Mode of Purchase (Retail, Non-Retail) - Trends & ... studies the market for the forecast period of 2016 ... 2.81 Billion by 2021 from USD 1.65 Billion in ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: